The House Energy and Commerce Committee yesterday released a report on the 340B Drug Pricing Program. “The 340B program is an important program that enjoys strong bipartisan support in Congress,” the report says. “The program helps reduce the prices of covered drugs for certain participating entities who, in turn, provide care for patients.” The report, which comes after two years of the committee examining the operation and oversight of the 340B program, includes a number of findings about the program, as well as 12 recommendations.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The AHA, 340B Health, Maryland Hospital Association and Mid-Atlantic Association of Community Health Centers July 9 filed an amicus brief in a federal district…
Headline
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…
Headline
A Mississippi judge July 1 denied Novartis Pharmaceuticals’ and PhRMA’s request for a preliminary injunction against enforcement of state law protecting 340B…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…